While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...